PSI 697

Drug Profile

PSI 697

Alternative Names: PSI-697; WAY-197697

Latest Information Update: 28 Sep 2011

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Quinolines; Salicylic acids; Small molecules
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atherosclerosis; Scleritis; Thrombosis

Most Recent Events

  • 28 Sep 2011 No development reported - Phase-I for Thrombosis in USA (PO)
  • 28 Sep 2011 No development reported - Phase-I for Scleritis in USA (PO)
  • 28 Sep 2011 No development reported - Phase-I for Atherosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top